Core Viewpoint - The company, Yongtai Biotech-B, announced the investment of idle raised funds into two structured deposit products with a total investment amount of 120 million yuan, aiming to enhance fund utilization efficiency while ensuring safety and liquidity [1]. Group 1: Investment Details - The company subscribed to two structured deposit products through the Bank of China on December 8, with a total investment of 120 million yuan [1]. - The first product, with an investment of 20 million yuan, is a principal-protected floating return type linked to the EUR/USD exchange rate, with a term of 20 days and an annualized yield ranging from 0.40% to 1.58% [1]. - The second product, with an investment of 100 million yuan, is also a principal-protected floating return type linked to the NZD/USD exchange rate, with a term of 62 days and an annualized yield ranging from 0.60% to 1.90% [1]. Group 2: Strategic Intent - The company stated that this investment is aimed at improving the efficiency of fund utilization while maintaining safety and liquidity in cash management [1]. - The board believes that the terms of the related transactions are fair and reasonable, aligning with the overall interests of the company and its shareholders [1]. Group 3: Company Background - Yongtai Biotech-B is a leading biopharmaceutical company in China, focusing on the research and commercialization of T-cell immunotherapy for nearly 18 years [1].
永泰生物-B：以1.20亿元闲置募集资金认购两款结构性存款产品